ArticleEye (London, England)2026
Long-term outcomes of the Paul glaucoma implant in a paediatric population: A retrospective cohort study.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate the long-term efficacy and safety of the Paul Glaucoma Implant (PGI) in a paediatric cohort.
methodsA retrospective review of 113 eyes from 83 paediatric patients (age range 4 months to 18 years, mean 9 ± 5 years) who underwent PGI implantation between June 2019 and April 2024. Intraocular pressure(IOP), medications, complications, and surgical success rates were assessed.
resultsThe mean preoperative IOP was 27.2 ± 6.2 mmHg. Postoperatively, IOP significantly decreased at all time points (p < 0.001), measuring 14.0 at 12 months, 13.7 at 24 months, 12.5 at 36 months, 12.5 at 48 months, and 13.7 at 60 months. The mean number of preoperative medications was 3.8 ± 0.8. Postoperatively, they were 0.9 at 12, 18, and 24 months, 0.7 at 36 months, 1.0 at 48 months, and 0.7 at 60 months (p < 0.001). 59% of eyes were medication-free at final follow-up. Thirty-nine eyes (35%) underwent Prolene stent removal (mean 9.7 months post-op), resulting in further IOP reduction (14.3 mmHg) and medication (0.8). Complete success rates (IOP ≤ 21 mmHg without medication) were 67.2% at 1 year, 58.2% at 2 years, 51.9% at 3 years, 50.1% at 4 years, and 49.3% at 5 years. Qualified success rates (IOP ≤ 21 mmHg with or without medication) were 91.2%, 88.5%, 85.8%, 85.0%, and 81.4% at the same intervals. 31(27.4%) eyes required further surgical intervention, most commonly for IOP control(21.2%). Major complications included tube exposure(2.7%) and hypotony(2.7%).
conclusionPGI demonstrates sustained IOP reduction, reduced medication burden, and an acceptable safety profile in refractory paediatric glaucoma. It represents an effective long-term surgical option for this challenging cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.